Investigators have determined that treating patients with an advanced form of age-related macular degeneration (AMD) with levodopa, a safe and readily available drug commonly used to treat Parkinson's disease, stabilized ...
Sep 10, 2020
0
19
(HealthDay)—For patients with early Parkinson disease, treatment with levodopa combined with carbidopa has no disease-modifying effect, according to a study published in the Jan. 24 issue of the New England Journal of Medicine.
Jan 24, 2019
0
1
Patients with Parkinson's disease are treated with levodopa, which is converted into dopamine, a neurotransmitter in the brain. In a study published on 18 January in the journal Nature Communications, scientists from the ...
Jan 21, 2019
0
431
The best-known treatment for Parkinson's disease isn't perfect. Named levodopa, the drug can treat the stiffness and slowness of movement associated with the debilitating disease.
Jul 18, 2018
0
3
New help may be on the way for people with dementia with Lewy bodies, which is the second most common neurodegenerative type of dementia after Alzheimer's disease. The disease can cause movement problems and issues such as ...
Jan 24, 2018
0
7
U.S. regulators have approved the first new drug in a decade for Parkinson's disease, a neurological disorder that causes tremors and movement difficulties.
Mar 21, 2017
0
0
(HealthDay)—For patients with Parkinson's disease (PD) receiving levodopa therapy and experiencing end-of-dose motor fluctuations, treatment with 50-mg/day opicapone is associated with a reduction in mean daily off-time, ...
Dec 28, 2016
0
4
(HealthDay)—An inhaled version of the Parkinson's drug levodopa can help when patients experience symptoms between doses of the pill form of the medication, according to a study published in the Oct. 12 issue of Science ...
Oct 13, 2016
0
4
(HealthDay)— Levodopa (L-dopa) might hold potential for preventing or treating macular degeneration, according to a study published online Oct. 30 in The American Journal of Medicine.
Nov 13, 2015
0
9
Although levodopa remains the "gold standard" to effectively control motor deficits in the treatment of early stage Parkinson's disease (PD), it loses effectiveness as the disease progresses. After four to six years of treatment ...
Feb 26, 2015
0
5
